Related Experiment Video

Updated: Aug 10, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins

M Jeschke1, W Wels, W Dengler

  • 1Friedrich Miescher Institute, Basel, Switzerland.

International Journal of Cancer
|March 3, 1995
PubMed

Insights

Novel recombinant toxins targeting epidermal growth factor receptors show promise for treating human adenocarcinomas. HRG beta I-ETA effectively reduced tumor growth in mice but higher doses caused liver toxicity.

Area of Science:

  • Biotechnology
  • Molecular Biology
  • Oncology

Background:

  • Human adenocarcinomas often overexpress epidermal growth factor (EGF) receptor family members (ErbB-1-4).
  • Recombinant toxins combining tumor-recognition and cytotoxic functions offer targeted anti-cancer therapy.
  • Heregulins (HRG) are ligands for ErbB receptors, making them suitable for targeted toxin delivery.

Purpose of the Study:

  • To construct and evaluate chimeric heregulin-toxin fusion proteins for targeted cancer therapy.
  • To assess the cytotoxic activity of these fusion proteins against human carcinoma cell lines.
  • To investigate the therapeutic potential and toxicity of HRG-ETA in a preclinical mouse model.

Main Methods:

  • In vitro recombination of gene fragments to create chimeric heregulin-toxin fusion proteins.
  • Construction of two fusion proteins: HRG alpha-ETA and HRG beta I-ETA, utilizing EGF-like domains of heregulin and Pseudomonas exotoxin A (ETA).
  • Assessment of cytotoxicity in mammary carcinoma cell lines (SK-BR-3, MDA-MB-453) and in vivo efficacy and toxicity studies in mice.

Main Results:

  • HRG beta I-ETA demonstrated high cytotoxicity against SK-BR-3 and MDA-MB-453 cell lines, while HRG alpha-ETA showed lower activity.
  • Cytotoxic activity correlated with ErbB-3 and/or ErbB-4 expression levels; high ErbB-2 expression alone did not confer sensitivity.
  • Treatment with HRG beta I-ETA at 0.4 mg/kg/day retarded transplanted human breast tumor growth in mice, but higher doses induced liver necrosis.

Conclusions:

  • Chimeric heregulin-ETA fusion proteins are effective cytotoxic agents against specific human adenocarcinomas.
  • ErbB-3 and/or ErbB-4 expression is critical for sensitivity to HRG-ETA.
  • HRG beta I-ETA shows therapeutic potential in vivo but requires careful dose management due to liver toxicity.

More Related Videos

Dual Bioluminescence Imaging of Tumor Progression and Angiogenesis10:56

Dual Bioluminescence Imaging of Tumor Progression and Angiogenesis

Published on: August 1, 2019

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.